Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome
Authors:
- Renata Lazari SandovalRSRenata Lazari Sandoval
- Cibele MasottiCMCibele Masotti
- Mariana Petaccia de MacedoMMMariana Petaccia de Macedo
- Maurício Fernando Silva Almeida RibeiroMRMaurício Fernando Silva Almeida Ribeiro
- Denis Leonardo Fontes JardimDJDenis Leonardo Fontes Jardim
- Artur KatzAKArtur Katz
- Anamaria Aranha CamargoACAnamaria Aranha Camargo
Open Access
- 1 July 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1141-1150
Abstract
PURPOSE Li-Fraumeni syndrome (LFS) is rare in the worldwide population, but it is highly prevalent in the Brazilian population because of a founder mutation, TP53 p.R337H, accounting for 0.3% of south and southeastern population. Clinical criteria for LFS may not identify all individuals at risk of carrying the Brazilian founder mutation because of its lower penetrance and variable expressivity. This variant is rarely described in databases of somatic mutations. Somatic findings in tumor molecular profiling may give insight to identify individuals who might be carriers of LFS and allow the adoption of risk reduction strategies for cancer. MATERIALS AND METHODS We determined the frequency of the TP53 p.R337H variant in tumor genomic profiling from 755 consecutive Brazilian patients with pan-cancer. This is a retrospective cohort from January 2013 to March 2020 at a tertiary care center in Brazil. RESULTS The TP53 p.R337H variant was found in 2% (15 of 755) of the samples. The mutation allele frequency ranged from 30% to 91.7%. A total of seven patients were referred for genetic counseling and germline testing after tumor genomic profiling results were disclosed. All the patients who proceeded with germline testing (6 of 6) confirmed the diagnosis of LFS. Family history was available in 12 cases. Nine patients (9 of 12) did not meet LFS clinical criteria. CONCLUSION The identification of the TP53 p.R337H variant in tumor genomic profiling should be a predictive finding of LFS in the Brazilian population and should prompt testing for germline status confirmation. (C) 2021 by American Society of Clinical OncologyKeywords
This publication has 44 references indexed in Scilit:
- ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencingGenetics in Medicine, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumoursClinical Endocrinology, 2014
- Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical TumorsJournal of Clinical Oncology, 2013
- Sarcomas in TP53 germline mutation carriersCancer, 2011
- Detailed haplotype analysis at theTP53locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effectHuman Mutation, 2009
- 2009 Version of the Chompret Criteria for Li Fraumeni SyndromeJournal of Clinical Oncology, 2009
- TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomesOncogene, 2007
- The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian familiesCancer Letters, 2007
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004